Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555740 | 0.87 | MRGPRX4 (0.60) | MRGPRX4ENPP2GPR84MAOB | |
| SCHEMBL2558160 | 0.87 | ENPP2 (0.61) | MRGPRX4ENPP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16687438 | 0.85 | ENPP2 (0.59) | MRGPRX4ENPP2RAB9ASMN1; SMN2POLB | |
| SCHEMBL177467 | 0.85 | HRH3 (0.54) | MRGPRX4ENPP2MCL1HRH3NPC1 | |
| SCHEMBL12260334 | 0.82 | MRGPRX4 (0.50) | MRGPRX4ENPP2MCL1HRH3SMN1; SMN2 | |
| SCHEMBL2561245 | 0.81 | ENPP2 (0.64) | MRGPRX4ENPP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16687434 | 0.81 | ENPP2 (0.68) | MRGPRX4ENPP2RAB9ASMN1; SMN2MAOB | |
| SCHEMBL15330536 | 0.80 | NR4A2 (0.56) | ENPP2NPC1RAB9AMAOAMAOB | |
| SCHEMBL31051000 | 0.80 | NR4A2 (0.56) | ENPP2NPC1RAB9AMAOAMAOB | |
| SCHEMBL16687432 | 0.80 | ENPP2 (0.59) | ENPP2HRH3KMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885ENPP2 147/4885MCL1 2648/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885ENPP2 147/4885MCL1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.